Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Martin Huber | M | 64 | 4 years | |
| Kristen Hege | M | 60 | 8 years | |
| Andrew Hack | M | 50 | 7 years | |
| Lawrence Alleva | M | 74 | 7 years | |
| Allene Diaz | F | 59 | 3 years | |
| Alejandra Carvajal | F | 50 | 3 years | |
| Willard Dere | M | 70 | 6 years | |
| Brian DeSchuytner | M | 46 | 5 years | |
| Ashish Mandelia | M | 50 | 5 years | |
| Chuck Miller | M | - | 4 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Andrea Corcoran | F | 61 |
Tolerx, Inc.
 Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 4 years |
| Sarah Carmody | F | - | 4 years | |
| Douglas J. Ringler | M | - |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 11 years |
| Wayne Foster | M | 55 | 7 years | |
| Elaine Jones | M | 69 | 3 years | |
| Herman Waldmann | M | - |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 11 years |
| Sara Nayeem | M | 75 | 6 years | |
| Arvin Yang | M | 48 | 3 years | |
| Carla Poulson | F | - | 2 years | |
| Dirk Huebner | M | 61 | 2 years | |
| David Spellman | M | 48 | 1 years | |
| Aoife Brennan | M | 48 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 3 years |
| Michael J. Kaufman | M | 66 | 5 years | |
| Donald Bergstrom | M | 52 | 4 years | |
| Titus M. F. M. Plattel | M | - |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 3 years |
| Teresa Regan | F | - |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 6 years |
| David Noskowitz | M | - | 2 years | |
| Mark O’Mahony | M | 53 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 11 years |
| John Freund | M | 70 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | - |
| Antonin Rollet de Fougerolles | M | 59 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 1 years |
| Louis Vaickus | M | - |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 9 years |
| Ian Smith | M | 58 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 7 years |
| James Niedel | M | 79 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 9 years |
| Stephen Hoffman | M | 70 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | - |
| John W. Littlechild | M | 72 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 7 years |
| Thomas A. Shea | M | 64 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 6 years |
| Dan Kisner | M | 77 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 10 years |
| Wayne T. Hockmeyer | M | 79 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 6 years |
| Robert Copeland | M | - | 5 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 39 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Donna M. Jarlenski
- Personal Network
